TNFRSF17 and Miyoshi myopathy: Monoallelic 16p deletion (encompassing TNFRSF17) has been identified in about 9% patients with newly diagnosed MM, particularly those harboring high-risk cytogenetic abnormalities, which may predispose them to biallelic TNFRSF17 loss upon relapse after BCMA-directed treatments [33].